People who use therapeutic ADHD stimulants (lisdexamfetamine, methylphenidate, dexamfetamine) and plan a psychedelic session are particularly at risk due to additive sympathomimetic load (higher heart rate/blood pressure, temperature, restlessness) and especially with ayahuasca due to the fact that the brew MAO-A inhibitory contains substances, which in combination with stimulants is known as a classic high-risk interaction mechanism (hypertensive crisis; possibly also serotonergic toxicity).
The level of evidence varies significantly per combination:
In practical terms, this means (high-level, non-personal medical advice):
This review is about therapeutic doses ADHD stimulants in adults with ADHD (comorbidities/other medication not specified). Where adult registration is lacking (e.g., some dexamphetamine products), adult shared care protocols have been used in addition, and uncertainty is explicitly stated.
The goal is risk assessment and harm reduction, not facilitating illegal substance use. Psychedelic sessions can be legal/clinical (ketamine, sometimes psilocybin/MDMA in trials) or non-clinical; risks and quality control differ significantly in these cases.
Important: stopping or pausing ADHD stimulants can cause rebound symptoms, sadness, and functional problems; product information also describes fatigue/depressive symptoms upon abrupt discontinuation after high/chronic use. Therefore, preferably change the dosage or timing of discontinuation. with prescribing doctor/pharmacist (especially with comorbid depression, cardiovascular conditions, substance use disorder).
Table 1. Key data ADHD stimulants (therapeutic) – including abbreviations and brand names (selection; not guaranteed to be complete worldwide)
| Dust | INN / generic | “Chemical” name (practical) | Abbreviations | Core mechanism | t½ (adults, order of magnitude) | Example adult dosage (order of magnitude) | Common brand names/variants (selection) |
|---|---|---|---|---|---|---|---|
| Lisdexamfetamine | lisdexamfetamine dimesylate/dimesilate | prodrug of dexamphetamine (d-amphetamine) coupled to L-lysine | LDX | prodrug → dexamphetamine; sympathomimetic stimulant | lisdexamfetamine <1 hour; dexamphetamine ~11 hours | start 30 mg qAM, max 70 mg/day | Elvanse / Elvanse Adult, Vyvanse, Tyvense (regional name), generics (depending on country) |
| Methylphenidate | methylphenidate (usually HCl) | racemic methylphenidate; prodrug-free stimulant | MPH | inhibits dopamine/noradrenaline reuptake (DAT/NET) | for PR product ~3.5 hours | examples of PR product: start 18 mg/day, max 72 mg/day (product dependent) | (NL‑context) Ritalin, Concerta, Equasym, Kinecteen, Medikinet; internationally, including PR/IR variants and dexmethylphenidate products |
| Dexamphetamine | dexamphetamine (usually sulfate) | d‑amphetamine / S‑(+)‑amphetamine, often as sulfate salt | DEX, d‑AMP | sympathomimetic amine; stimulant | ~10.2 hours (Tentin SmPC) | adult ADHD (off-label in some regions): start 5 mg twice daily, max 60 mg/day distributed (protocol-dependent) | Tent (NL), Amfexa/Attentin (EU/UK variants), Dexedrine/Zenzedi/Dextrostat (US names; country dependent) |
MAOI interaction as a “hard” red flag: all three stimulants have a in official product information (contra-)indication for concomitant use with MAO inhibitors, typically “not together and not within 14 days”.
Pharmacodynamic accumulation (most common):
Stimulants increase sympathetic tone (heart rate, blood pressure, alertness). Classical psychedelics (psilocybin/LSD) and MDMA also cause autonomic activation; in a controlled study, blood pressure, heart rate, and temperature increased after LSD, MDMA, and d-amphetamine by relevant percentages. systolic hypertension >140 mmHg after each of these means.
Serotonergic toxicity (selective, but potentially serious):
MDMA strongly increases serotonergic activity; serotonin syndrome is rarely seen in clinical trials, but cases have been described in pharmacovigilance data (FAERS) associated with MDMA exposure. with co-intake of serotonergic co-agents, including amphetamines/stimulants.
Core features of serotonin syndrome are neuromuscular signs (clonus/hyperreflexia), autonomic instability, and changes in mental status; this is speed.
MAOI mechanism (high risk, ayahuasca-relevant):
β-carbolines in ayahuasca inhibit MAO-A and increase/prolong monoaminergic signals. Stimulants and MAO inhibitors are a classic risk combination for hypertensive crisis and other toxic outcomes; official stimulant SmPCs explicitly list this as a contraindication within 14 days.
Serious reactions are also described in the literature on MAOI combinations with stimulant + MAOI (historical case studies), which strengthens the plausibility for ayahuasca.
Legend of evidential strength (practical):
A = direct human research or formal clinical protocol with concrete stopping rules;
B = strong mechanistic basis + clinical warnings/case studies;
C = plausible pharmacology + harm-reduction consensus, but few direct data;
D = primarily plausibility/experience, explicit lack of data.
Table 2. Interaction matrix (brief explanation per combination)
| Psilocybin | MDMA | Ketamine/(es)ketamine | LSD | Ayahuasca | |
|---|---|---|---|---|---|
| Lisdexamfetamine | Additive: ↑HR/↑BD, more restlessness/anxiety → higher risk of a bad trip (C). | Additive + serotonergic: ↑HR/↑BD/↑T°, risk of hyperthermia; serotonin syndrome possible with poly-drug; clinical protocol advises stopping ~5 t½ days before and 10 days after (A/B). | Particularly hemodynamic: additional BP increase; monitor/consider skipping morning dose (B). | Additive: ↑autonomic activation; increased risk of overstimulation/panic; limited data (C). | High risk (MAO‑A): stimulant + MAOI-like mechanism → hypertensive crisis; standard “not together” + often 14 days interval (B/A). |
| Methylphenidate | Additive: ↑HR/↑BD, more anxiety/headache; Dutch harm‑reduction: research lacking (C). | Direct evidence: co-administration ↑hemodynamics and side effects; no enhancement of desired effects (A). | Additional BD increase; official warning “monitor BD with psychostimulants” (B). | Little direct data; Dutch sources do not mention “serious interactions known” but uncertain (C). | High risk: methylphenidate contraindicated with MAOIs within 2 weeks; ayahuasca contains MAOI-like components → strongly advised against (B/A). |
| Dexamphetamine | Similar to LDX (active stimulant): additive autonomic/anxiety (C). | Additive + serotonergic: increased risk of hyperthermia/hypertension; serotonin syndrome possible with poly-drug; protocol strategy (5 t½ before, 10 days after) is the most concrete (A/B). | Additional BD rise; monitor; often “skip morning” as practice advice (B). | Dutch Q&A: “no dangerous interaction known”, but increased risk of panic/overstimulation (C). | High risk: dexamphetamine contraindicated with MAOIs within 14 days; ayahuasca = MAO-A inhibition → strongly advised against (B/A). |
Methylphenidate + MDMA (human co-administration study):
In a double-blind placebo-controlled crossover study, methylphenidate and MDMA were administered alone and in combination; co-administration led to significantly higher hemodynamic and side effect scores than each remedy separately.
MDMA-assisted therapy protocol (formal trial setting):
A MAPS protocol describes that participants with ADHD may use stimulants, but that they must these discontinue before ≥ five half-lives before every MDMA session and that restarts 10 days after the session is not permitted. This is one of the few explicit, written stop rules for this combination.
General autonomic load of MDMA/LSD/stimulant (context for cumulative risk):
A controlled comparison showed that LSD, MDMA, and d-amphetamine all increase blood pressure/heart rate/temperature and that clinically relevant systolic hypertension occurred in the study population after these substances. This supports the “stacking mechanism” as a plausible core pathway in combinations.
MDMA hyperthermia and treatment (clinical toxicology):
MDMA can cause a dose-dependent rise in core temperature; treatment of severe sympathomimetic toxicity/hyperthermia focuses on supportive care (including sedation, IV fluids, and cooling). This explains why additional sympathetic stimulation (such as by ADHD stimulants) is theoretically risky.
(Es)ketamine + psychostimulants (official product information/clinical literature):
EMA product information for esketamine reports transient increases in blood pressure and emphasizes monitoring; secondary clinical reviews explicitly state that combination with psychostimulants may further increase blood pressure and therefore requires monitoring.
Ayahuasca pharmacology (MAO‑A inhibition) as the basis for interaction risk:
Review literature describes that β-carbolines (harmine/harmaline/THH) reversibly inhibit MAO-A and inhibit DMT degradation; with this, the MAOI interaction principle is pharmacologically well substantiated.
Dutch harm reduction:
Experience-based / Q&A practice:
Retreat screening (anecdotal/clinical-administrative, not RCT evidence):
An ayahuasca medical guideline states that SSRIs must be tapered off under supervision and lists “other medications that must be discontinued”, including amphetamines (incl. Adderall) and methylphenidate (Ritalin), with explicit reference to 2-week windows for some agents (such as St. John's wort) and the general MAOI compatibility principle. This reflects screening in practice, not controlled efficacy studies.
Because comorbidity and dosages are unknown, the most robust framework is:
Important nuance: “Wash-out” is no magic; it reduces pharmacological overlap, but not psychological or contextual risks (sleep deprivation, dehydration, stress, set/setting). Moreover, stopping the stimulant can lead to rebound and poorer coping during a session.
Table 3. Practical stop/continue advice per pairing (with strength of evidence)
| Combination | Main risk | Stimulant Day? | Target washout before session (indicative) | Restart after session | Evidence |
|---|---|---|---|---|---|
| LDX + psilocybin | ↑BD/↑HR, anxiety/overstimulation | Often skip to reduce peak sympathy (only in consultation regarding daily functioning) | Conservative: ≥ 2–3 days (≈5×11 hours) if you follow a “5 half-lives” approach; direct evidence is lacking | When stable (sleep, BD) back; no data | C |
| MPH + psilocybin | Same, plus headache/restlessness | Often “days off” in harm reduction; data missing | Indicative: ~1 day (5×3.5 hours ≈ 18 hours) | When stable; no data | C |
| DEX + psilocybin | idem | Skip often | Indicative: 2–3 days (5×10.2 hours ≈ 51 hours) | When stable; no data | C |
| LDX + LSD | ↑BD/↑HR, panic/overstimulation, long duration LSD | Many sources: no “dangerous” interaction known but higher risk of a bad trip → skip often | Same indication as psilocybin: 2–3 days as a conservative | When stable | C |
| MPH + LSD | idem | No serious interactions known, but uncertain → often skip | ~1 day indicative | When stable | C |
| DEX + LSD | idem | No dangerous interactions known; however, more panic/overstimulation → skipping the day makes sense | 2–3 days indicative | When stable | C |
| LDX + MDMA | ↑BD/↑HR/↑T°, hyperthermia, serotonin toxicity with polydrug | In clinical protocols: not day of | ≥5 half-lives before (≈2–3 days) = protocol logic; additionally often “not the day before” in harm reduction | Do not restart for 10 days in MAPS protocol (clinically conservative) | A/B |
| MPH + MDMA | ↑hemodynamics/side effects | Avoid; not day of | Not universal; but co-administration is demonstrably heavier → minimum “no overlap” | Protocol-conservative: 10 days; practice varies | A |
| DEX + MDMA | ↑BD/↑HR/↑T°, serotonin toxicity with poly-drug | Avoid; not day of | 2–3 days (5×10.2 hours) as a protocol analogy | Protocol conservative: 10 days | A/B |
| LDX + ketamine/(es)ketamine | especially ↑BD/↑HR during session | Many clinics: skip morning dose; vital monitoring | Often no multi-day washout is needed if BD is okay and monitoring is present; evidence primarily depends on the label/clinic practice. | After session when BD/HR returns to normal; individual | B |
| MPH + ketamine/(es)ketamine | idem | idem | idem | idem | B |
| DEX + ketamine/(es)ketamine | idem | idem | idem | idem | B |
| All stimulants + ayahuasca | hypertensive crisis/MAOI reaction; possible serotonin toxicity | Do not combine | Conservative: treat ayahuasca as MAOI exposure → ≥14 days distance (SmPC logic) and only with medical supervision; retreats often require discontinuation | Also conservative: social distancing and medical assessment | B/A |
For clinicians (treating physicians/ketamine or trial teams)
For participants/clients (practical, harm-reduction; not a substitute for medical advice)
Sources: